RBC Capital Downgrades Fulcrum Therapeutics to Sector Perform, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has downgraded Fulcrum Therapeutics from Outperform to Sector Perform and reduced its price target from $15 to $4.
September 13, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has downgraded Fulcrum Therapeutics from Outperform to Sector Perform, significantly lowering the price target from $15 to $4.
The downgrade from Outperform to Sector Perform by RBC Capital suggests a less optimistic outlook for Fulcrum Therapeutics. The drastic reduction in the price target from $15 to $4 indicates a significant decrease in expected future performance, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100